- Trial phase
- Phase 1/2
- Time to market
- Several years away, if ever. The drug is in Phase 1/2 dose-escalation; a registrational path has not been defined.
- Why 4/10
- The next hard, dated catalyst is the oral presentation of initial Phase 1/2 data at the 68th ASH Annual Meeting in December 2026. That data has already been previewed (4 confirmed responses in 11 patients), so the ASH presentation is a full-data readout of already-telegraphed early results, not a binary approval or pivotal readout.
Watch for the full ASH 2026 oral presentation in December 2026 for deeper efficacy and safety details (duration of response, cytokine release syndrome rates). The early 36% response rate in heavily pretreated patients is encouraging but very early. Moderna has a second T-cell engager (mRNA-2151) in ovarian cancer that could validate the platform if mRNA-2808 data holds up.
Price Chart
Executive Summary
mRNA-2808 is Moderna's first clinical-stage mRNA-based T-cell engager, targeting relapsed or refractory multiple myeloma. It is an early-stage (Phase 1/2) asset that uses Moderna's mRNA platform to make the body produce three anti-cancer proteins simultaneously. On November 4, 2026, Moderna announced initial data showing 4 confirmed responses among 11 heavily pretreated patients, and the data was accepted for oral presentation at the ASH 2026 annual meeting in December. While the early efficacy signal is encouraging for a proof-of-concept, the drug is years from any regulatory decision, and multiple myeloma is a competitive landscape with approved bispecific antibodies and CAR-T therapies. mRNA-2808 represents a small part of Moderna's broad pipeline; the company's valuation is driven primarily by its COVID-19 vaccine franchise and its personalized cancer vaccine (intismeran) partnership with Merck.
How It Works
mRNA-2808 is an mRNA-based T-cell engager (TCE). It works by delivering genetic instructions (mRNA) into the patient's body that instruct their own cells to produce three cancer-fighting proteins at once. These proteins help redirect the patient's immune T-cells to recognize and kill multiple myeloma cancer cells. It is a "multiplexed" approach, meaning a single mRNA drug encodes multiple therapeutic proteins.
Trial Status
First patient dosed in November 2025. Initial data from 11 heavily pretreated relapsed/refractory multiple myeloma patients showed 4 confirmed responses (36% response rate). The data was selected for oral presentation at the 68th ASH Annual Meeting in December 2026. The trial is ongoing and enrolling.
The Two-Sided Case
Upcoming Catalysts
- Oral presentation of full Phase 1/2 data at the 68th ASH Annual Meeting in December 2026.
- Dose-escalation updates and potential expansion cohort data as the Phase 1/2 study continues to enroll.
- Potential initiation of a Phase 2 expansion cohort or combination study if safety and efficacy data remain favorable.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Moderna, Inc. 8-K MRNA ·Originating report